Phase ii dose patients receive oral imatinib mesylate. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy8

K562 Cells Philadelphia Chromosome Cell Line, Tumor Chromosomes, Human, Pair 9 Neoplastic Stem Cells Myeloid Progenitor Cells Cells, Cultured Bone Marrow

Diseases38

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Neoplasms Leukemia, Myeloid, Chronic-Phase Neutropenia Blast Crisis Hypereosinophilic Syndrome Nausea Thrombocytopenia Hypopigmentation Gastrointestinal Neoplasms Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Philadelphia Chromosome Vomiting Stomatitis Lung Neoplasms Dermatofibrosarcoma Mastocytosis, Systemic Fatigue Fibromatosis, Aggressive Carcinoma, Non-Small-Cell Lung Disease Progression Leukemia, Myeloid, Accelerated Phase Neoplasm Recurrence, Local Lichenoid Eruptions Neoplasm, Residual Recurrence Neoplasm Metastasis Primary Myelofibrosis Precursor Cell Lymphoblastic Leukemia-Lymphoma Peritoneal Neoplasms Scleroderma, Systemic Histiocytoma, Malignant Fibrous Brain Neoplasms Fibrosis Graves Ophthalmopathy Bone Neoplasms Leukemia

Chemicals and Drugs49

Benzamides Piperazines Pyrimidines Antineoplastic Agents Fusion Proteins, bcr-abl Protein Kinase Inhibitors Proto-Oncogene Proteins c-kit Receptor, Platelet-Derived Growth Factor alpha Receptor, Platelet-Derived Growth Factor beta Paclitaxel Taxoids Camptothecin Protein-Tyrosine Kinases Proto-Oncogene Proteins c-abl Deoxycytidine Epothilones Antineoplastic Agents, Phytogenic Quinazolines Topotecan Pyridines Carboplatin Cisplatin Fluorouracil Receptors, Platelet-Derived Growth Factor Enzyme Inhibitors Pyrazines Antibodies, Monoclonal, Humanized Thiazoles Pregnatrienes Doxorubicin Proto-Oncogene Proteins c-sis Interferon-alpha Harringtonines Pyrroles mRNA Cleavage and Polyadenylation Factors Ketones Furans Indoles Rifabutin Hydroxyurea Platelet-Derived Growth Factor STAT5 Transcription Factor RNA, Messenger Stem Cell Factor Cytarabine Oncogene Proteins, Fusion Antigens, CD34 Neoplasm Proteins Antibodies, Monoclonal

Analytical, Diagnostic and Therapeutic Techniques and Equipment35

Maximum Tolerated Dose Drug Administration Schedule Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Infusions, Intravenous Administration, Oral Area Under Curve Clinical Trials, Phase II as Topic Cytogenetic Analysis Clinical Trials, Phase I as Topic Drug Evaluation Remission Induction Disease-Free Survival Metabolic Clearance Rate Survival Analysis Drug Approval Survival Rate Neoplasm Staging Combined Modality Therapy Salvage Therapy Follow-Up Studies Treatment Failure Prognosis Neoadjuvant Therapy Reverse Transcriptase Polymerase Chain Reaction In Situ Hybridization, Fluorescence Inhibitory Concentration 50 Kaplan-Meier Estimate Cohort Studies Clinical Trials as Topic Immunohistochemistry Blood Cell Count Transplantation, Homologous Blotting, Western Hematopoietic Stem Cell Transplantation

Phenomena and Processes21

Maximum Tolerated Dose Dose-Response Relationship, Drug Area Under Curve Drug Resistance, Neoplasm Genes, abl Philadelphia Chromosome Time Factors Metabolic Clearance Rate Metabolic Detoxication, Phase II Half-Life Apoptosis Drug Synergism Cell Proliferation Mutation Phosphorylation Gene Expression Regulation, Leukemic Chromosomes, Human, Pair 9 Signal Transduction Inhibitory Concentration 50 Cell Survival Blood Cell Count

Disciplines and Occupations2

Cytogenetics Immunohistochemistry

Anthropology, Education, Sociology and Social Phenomena2

Drug Approval United States Food and Drug Administration

Information Science1

Health Care13

Treatment Outcome Area Under Curve Clinical Trials, Phase II as Topic Clinical Trials, Phase I as Topic Disease-Free Survival Survival Analysis Survival Rate Follow-Up Studies Treatment Failure United States Food and Drug Administration Kaplan-Meier Estimate Cohort Studies Clinical Trials as Topic

Anatomy Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Information Science Health Care

Benzamides Piperazines Pyrimidines Leukemia, Myelogenous, Chronic, BCR-ABL Positive Antineoplastic Agents Gastrointestinal Stromal Tumors Maximum Tolerated Dose Fusion Proteins, bcr-abl Drug Administration Schedule Neoplasms Protein Kinase Inhibitors Proto-Oncogene Proteins c-kit Treatment Outcome Dose-Response Relationship, Drug Antineoplastic Combined Chemotherapy Protocols Infusions, Intravenous Receptor, Platelet-Derived Growth Factor alpha Leukemia, Myeloid, Chronic-Phase Neutropenia Administration, Oral Area Under Curve Drug Resistance, Neoplasm Receptor, Platelet-Derived Growth Factor beta Paclitaxel Clinical Trials, Phase II as Topic Blast Crisis Hypereosinophilic Syndrome Genes, abl Nausea Taxoids Camptothecin Thrombocytopenia Cytogenetic Analysis Clinical Trials, Phase I as Topic Protein-Tyrosine Kinases Proto-Oncogene Proteins c-abl Hypopigmentation Deoxycytidine Gastrointestinal Neoplasms K562 Cells Epothilones Drug Evaluation Antineoplastic Agents, Phytogenic Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Philadelphia Chromosome Quinazolines Remission Induction Time Factors Vomiting Disease-Free Survival Topotecan Stomatitis Pyridines Metabolic Clearance Rate Survival Analysis Carboplatin Cisplatin Fluorouracil Receptors, Platelet-Derived Growth Factor Enzyme Inhibitors Lung Neoplasms Dermatofibrosarcoma Drug Approval Mastocytosis, Systemic Pyrazines Survival Rate Metabolic Detoxication, Phase II Fatigue Antibodies, Monoclonal, Humanized Neoplasm Staging Cell Line, Tumor Thiazoles Pregnatrienes Combined Modality Therapy Fibromatosis, Aggressive Doxorubicin Proto-Oncogene Proteins c-sis Salvage Therapy Carcinoma, Non-Small-Cell Lung Disease Progression Half-Life Interferon-alpha Harringtonines Apoptosis Leukemia, Myeloid, Accelerated Phase Neoplasm Recurrence, Local Follow-Up Studies Drug Synergism Cell Proliferation Pyrroles Treatment Failure Prognosis Lichenoid Eruptions Mutation Phosphorylation Neoplasm, Residual mRNA Cleavage and Polyadenylation Factors Ketones Recurrence Furans

No FAQ available that match "phase ii dose patients receive oral imatinib mesylate"